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ABSTRACT The aim of this work was the in vitro expression of the recombinant fusion (F) protein of Newcastle disease virus
(NDV). The pBT7‐N‐His‐Fusion‐NDV expression plasmid which carries the recombinant F protein encoding gene from local
Indonesian isolates, was prepared and transformed into Escherichia coli BL21 (DE3). To detect bacterial colonies carrying
the recombinant plasmid, a restriction endonuclease analysis was performed using the EcoRI restriction endonuclease.
These results showed that the pBT‐N‐His‐Fusion‐NDV plasmid was successfully isolated with a size of 4.601 bp, and three
recombinant plasmids carrying the gene coding for the recombinant F protein of NDV were obtained. Selected recombinant
plasmids were then in vitro by using a cell‐free protein expression system followed by visualization of the recombinant F
protein on a 12% SDS‐PAGE gel both by Coomassie Brilliant Blue staining andWestern blotting. Recombinant F protein was
successfully in vitro expressed by using a cell‐free protein expression system as indicated by a specific single protein band
with a molecular mass of 25.6 kDa.
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1. Introduction
Newcastle disease (ND) is a poultry infectious viral dis­
ease which has become a major problem in the poultry in­
dustry in developing countries. Office International des
Epizooties (OIE) categorizes ND in the A list of animal
diseases, which includes infectious diseases with rapid and
serious spreading and affecting public health and socio­
economic communities ([OIE] Office Internationalof Epi­
zootics 2015). As other infectious viral disease outbreak
which had been reported in Indonesia poultry industry,
such as avian influenza (Njoto et al. 2018), infectious bur­
sal disease (Parede et al. 2003), and avian encephalomyeli­
tis (Haryanto et al. 2016). An outbreak of ND can cause
a devastating effect as it causes almost 100% mortality in
susceptible poultry (Alexander et al. 2012). ND was also
reported to have a significant economic effect on the poul­
try industry in Indonesia (Dharmayanti et al. 2014). New­
castle disease is caused by avian paramyxovirus serotipe­1
(APMV­1) virus, which is also known as Newcastle dis­
ease virus or NDV (Alexander 2003). NDV belongs to
the genus Avulavirus, subfamili Paramyxovirinae, famili
Paramyxoviridae, and orderMononegavirales (King et al.
2012). NDV genome is a negative sense single stranded
RNA (ssRNA) encoding six viral proteins, namely nucleo­
capsid (N), phosphoprotein (P), matrix (M), fusion protein
(F), hemaglutinin­neuraminidase (HN), and RNA poly­
merase (L) (De Leeuw and Peeters 1999; King et al. 2012).
NDV infection on the host cell is mediated by two surface
viral glycoproteins, the hemaglutinin­heuraminidase (HN)
protein and fusion (F) protein (Chang and Dutch 2012).
F protein in NDV plays an essential role in the viru­
lence of the virus (Dortmans et al. 2011). F protein can also
induce protective immunity against NDV infection (Arora
et al. 2010). Kim et al. (2013) reported that the F protein of
NDV is a major part of protective immunity in developing
genotype­matched vaccine. NDVF protein consists of 553
amino acids which are synthesized as F0 inactive precur­
sor (Morrison 2003). F0 protein can be cleaved by cellular
protease resulting in active F1 and F2 proteins. F protein
is processed in trans Golgi in a mammalian cell, which
produces the active form of F1­F2 protein with a disulfide
bond (Lamb and Parks 2007). The specificity of cleavage
F protein is determined by the amino acid sequence at the
region of cleavage sites and varied between strain types.
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In the cleavage site of F protein, low virulence NDV has
one or two base amino acids. Therefore, low virulence
NDV is not sensitive to intracellular protease enzyme and
depends on extracellular protease in the respiratory and en­
teric systems of the host cells. Highly virulence NDV has
multi base amino acids in the cleavage site so that it can be
recognized by intracellular protease enzyme. Amino acid
sequence at the cleavage site of F0 protein is one of the fac­
tors that determines the systemic spreading and virulence
of NDV. Highly virulence NDV contains lysine (K) and
arginine (R) amino acids with 112R­R­Q­R/K­R116 motive
at C terminus F2 and phenylalanine (F) amino acid at 117
position at N terminus protein F1 (Ganar et al. 2014).
Newcastle disease outbreak was reported in 2009­
2010 in poultry farms in Indonesia, which caused death
on 70­80% of the total number of chickens (Dharmayanti
et al. 2014). Analysis on the amino acid identity of F and
HN protein sequences from eight isolates NDV, which
caused the outbreak indicated antigenic differences from
La Sota and B1 vaccine strains (Xiao et al. 2012). A vac­
cination program has been conducted to prevent and over­
come ND ([OIE] Office International of Epizootics 2012).
However, ND outbreaks still continue to happen in In­
donesia. The outbreak is a result from antigenic differ­
ences betweenNDV strain causing the outbreak in the field
with NDV strain used in the available commercial vaccine.
Therefore, the vaccination program did not provide opti­
mal protection in the poultry post vaccination (Xiao et al.
2012; Dharmayanti et al. 2014).
A recombinant vaccine is a vaccine containing anti­
gen of a pathogenic agent that can induce the host immu­
nity against the pathogenic agent (Grand et al. 2012). The
recombinant vaccine is safer and more stable compared
to conventional live vaccines. A recombinant vaccine is
created by cloning a certain encoding gene of an immuno­
genic protein, expressed and purified the recombinant pro­
tein, and formulated it to be a vaccine (Nascimento and
Leite 2012). Regardless of the type of ND vaccines in
use, all vaccinated birds were fully protected from disease.
All vaccinated and challenged birds show significant sero­
conversion after 14 days of challenge. However, some
vaccinated birds were reported to shed the challenge virus
from their oro­pharynx and cloaca, even though they are
significantly lower in titers than unvaccinated challenged
control birds (Jeon et al. 2008).
The development of NDV vaccines based on the phy­
logenetic similarity to NDV in the time of the outbreak can
provide better protection against ND (Miller et al. 2007).
Therefore, one of the attempts to prevent ND on poultry
in Indonesia is developing an ND vaccine based on local
isolates originated in Indonesia. This work aimed to ex­
press recombinant F protein of NDV from pBT7­N­His­
Fusion­NDV expression vector which carries the F pro­
tein encoding gene from NDV local isolate by a cell­free
protein expression system. Recombinant NDV F protein
obtained from the expression is expected to be a candidate
for the recombinant F vaccine to prevent ND on poultry in
Indonesia.
2. Materials and Methods
2.1. Preparation of pBT7‐N‐His‐Fusion‐NDV recombi‐
nant plasmid
The expression vector used in this work had been prepared
by Haryanto et al. (2016) and Wulanjati et al. (2018) by
subcloning the F protein encoding gene of NDV from lo­
cal isolate in Kulon Progo, Indonesia (0663/04/2013) into
pBT7­N­His expression vector. The design of the recom­
binant plasmid vector is shown in Figure 1.
2.2. Transformation of recombinant plasmid into Es‐
cherichia coli BL21 (DE3)
Transformation of DNA plasmid pBT7­N­His­Fusion­
NDV was carried out using competent Escherichia coli
BL21 (DE3) strain by carefully transferring DNA plasmid
into a tube containing competent cells. Plasmid DNA and
competent cells were mixed gently and placed on ice for
20 min. Then, the cells were heat­shocked at 42 °C for 60
s. The mixture of plasmid DNA and competent cells were
placed immediately on ice for 3 min. The mixture was
then put into the culture medium, 10 mL of Luria Bertani
(LB) (Oxoid) supplemented with 100 µg/mL ampicillin
(Gold Biotechnology), and incubated at 37 °C overnight.
The transformation of the recombinant plasmid intoE. coli
generated eight growing colonies of E. coli carrying re­
combinant plasmid. The eight colonies of bacteria were
extracted using Presto Mini Plasmid kit (Geneaid) to ob­
tain the recombinant plasmid DNA.
FIGURE1Design of recombinant plasmid pBT7‐N‐His‐FusionNDV
(4,601 bp). F protein encoding gene of NDV (642 bp) was sub‐
cloned into the Eco RI restriction site
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2.3. Restriction endonuclease analysis of recombinant
plasmid vector by EcoRI enzyme
The screening of recombinant plasmid pBT7­N­His­
Fusion­NDV was carried out by digestion of recombinant
plasmid by EcoRI enzyme (Thermo Fisher Scientific) in
a total volume of 10 µL. The samples were then incu­
bated at 37 °C for 3 h. The digestion product was then
visualized on a 1.5% agarose gel electrophoresis with Flu­
orosafe (Genetika Science Indonesia) staining. The re­
striction product was analyzed under UV light in the dark
room.
2.4. In vitro expression of recombinant FpProtein of
NDV by the cell‐free protein expression system
The in vitro expression of recombinant F protein of NDV
from Indonesian local isolates was performed by a cell­
free protein expression system using the AccuRapid pro­
tein expression kit (Bioneer) according to the standard
manual procedure. The expressed recombinant F protein
of NDVwas then visualized by electrophoresis on an SDS­
PAGE gel followed by Coomassie Brilliant Blue R­250
(Thermo Fisher Scientific) staining.
2.5. SDS‐PAGE with Coomassie Brilliant Blue staining
Before SDS­PAGE, the samples were denatured at 95 °C
for 5 min, then put into ice for about 30 min. Each sample
(5 µL) was loaded on a 5% stacking gel and separated on a
12% resolving SDS­PAGE gel. The protein concentration
of each sample was as follow 1.39 µg/µL for sample 1,
0.13 µg/µL for sample 2, 0.88 µg/µL for sample 3, and
1.52 µg/µL for positive control. The SDS­PAGE gel was
run at 100 Volt for 1 h, and then it stained with Coomassie
Brilliant Blue R­250.
2.6. Western blotting
The expressed recombinant F protein of NDV was visu­
alized by Western blotting. As a positive control, Ae­
quore courulescens GFP fluorescent protein (AcGFP) with
a molecular weight of 28.0 kDa on lane with a concentra­
tion of 1.52 µg/µL was used. The recombinant F protein
was separated by a 12% resolving SDS­PAGE gel. They
were then electrotransferred onto polyvinylidene difluo­
ride (PVDF) membrane (Merck) for detecting the recom­
binant F protein. Western blotting preparation was per­
formed by blocking the membrane by the blocking so­
lution [1% BSA (Thermo Fisher Scientific) dissolved in
0.5% Tween­PBS (Sigma­Aldrich)]. The PVDF mem­
brane was then incubated at room temperature for 1 h. Af­
ter washed three times in washing solution (0.05% Tween­
PBS), the PVDF membrane was probed with a mouse
monoclonal antibody, anti­6x histidine (his)­tag antibody
(Thermo Fisher Scientific) as the primary antibody in
a 1:2,000 dilution. The membrane was then incubated
and shaken overnight at 4 °C. After three time wash­
ing, the PVDF membrane was subsequently incubated
with the secondary antibody, alkaline phosphatase (AP)­
conjugated goat antimouse IgG antibody (Thermo Fisher
Scientific) in a 1:15,000 dilution. The PVDF membrane
was then incubated and shaken at room temperature for 1
h. After two time washing, the immunological reaction
was visualized by adding NBT­BCIP (Thermo Fisher Sci­
entific) substrate onto the PVDF membrane.
3. Results and Discussion
3.1. Transformation plasmid pBT‐7‐N‐His‐Fusion NDV
into E. coli BL 21and visualization of recombinant
NDV fusion protein expression
The transformation of pBT7­N­His­Fusion­NDV recom­
binant plasmid was performed initially on E. coli BL21
(DE­3) competent cell. The transformation result indi­
cated that there were eight colonies of E. coli grew on
agar LB medium (Figure 2). To confirm the result of the
recombinant plasmid transformation, three from the eight
colonies were selected for DNA isolation of recombinant.
The next process was restriction endonuclease analysis by
digestion recombinant plasmid pBT7­N­His­Fusion­NDV
using EcoRI restriction enzyme. Recombinant plasmid di­
gestion resulted two DNA bands in size of 3,959 bp (plas­
mid) and 642 bp (insert gene), respectively, while the undi­
gested recombinant plasmid was observed to be 4,601 bp
in size (Figure 3). The undigested recombinant plasmid
which was run by electrophoresis in agarose gel showed
three bands of DNA because it had three forms of confor­
mation: relaxed circular form, linearized form, and super­
helix form (De Mattos et al. 2004).
In Figure 4, electrophoresis using SDS­PAGE of
recombinant F protein on the agarose gel 12% with
Coomassie Brilliant Blue staining showed that recombi­
nant F protein of NDV could be expressed as a thick pro­
FIGURE 2 Eight growing colonies of E. coli BL21 carrying recom‐
binant plasmid pBT7‐N‐His‐Fusion‐NDV in LB agar medium with
ampicillin.
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FIGURE 3 The digestion result of recombinant plasmid pBT‐N‐His‐
Fusion‐NDV by using Eco RI enzyme. No. 1 is recombinant plasmid
of Colony‐1 (C‐1) was digested by Eco RI, No. 2 is an intact recom‐
binant of C‐1, No. 3 is recombinant plasmid of Colony‐2 (C‐2) was
digested by Eco RI. No. 4 is an intact recombinant plasmid of C‐2,
No. 5 is recombinant plasmid of Colony‐3 (C‐3) was digested by
Eco RI, No. 6 is an intact recombinant plasmid of C‐3.
tein band with the molecular weight of 25.6 kDa (lane 1,
2, 3). Meanwhile, AcGFP with the molecular weight of
28.0 kDa on lane (+) appeared as the positive control. The
recombinant F protein of NDVwhich expressed using cell­
free protein expression system found in the supernatant
after incubated for 3 h at 30 °C. It indicated that the ex­
pressed recombinant F protein of NDV in this expression
system is a soluble protein. This soluble protein can be re­
activated and followed by a refolding process with dilution
or dialysis method in refolding buffer to obtain active sol­
uble protein (Middelberg 2002; Burgess 2009; Yang et al.
2011).
3.2. Western blotting
Western blotting using a mouse antihistidin­tag antibody
as the primary antibody and goat antimouse antibody as
the secondary antibody was conducted to assure the result
of recombinant F protein of NDV expression. The result
of Western blotting can be seen in Figure 5. It showed a
FIGURE 4 SDS‐PAGE with Coomassie Brilliant Blue staining of the
expressed recombinant F protein of NDV into E. coli extract. No.
1 is a recombinant plasmid of Colony‐1 (C‐1), No. 2 is a recombi‐
nant plasmid of Colony‐2 (C‐2). No. 3 is a recombinant plasmid of
Colony‐3 (C‐3), (+) is positive control, (‐) is negative control
FIGURE 5 Western blotting of the recombinant F protein of NDV
M = protein marker. No. 1, 2, and 3 are Colony‐1 (C‐1), Colony‐2
(C‐2), and Colony‐3 (C‐3) , respectively. (+) = positive control. (‐) =
negative control.
specific protein band with a molecular weight of 25.6 kDa
at lane 1, 2, 3. The positive control AcGFP protein with
a molecular weight of 28.0 kDa could be observed in lane
(+). Both recombinant F protein of NDV in lane 1, 2, 3
and AcGFP in lane (+) were fusion protein with 6x his­tag
at the N­terminus end.
3.3. Discussion
The recombinant expression plasmid that we designed
pBT7­N­His­Fusion­NDV (4,601 bp) was derived from
pBT7­N­His plasmid which having the origin of replica­
tion (ORI) from pUC plasmid. This plasmid carried the F
protein encoding gene fromNDVwhich was isolated from
Indonesian local isolate. Recombinant F protein expressed
from pBT7­N­His­Fusion­NDV will be prepared as a can­
didat vaccine for viral diseases, ND, in poultry based on lo­
cal isolate virus. The expression of recombinant F protein
from pBT7­N­His­Fusion­NDV plasmid vector was con­
trolled by T7 promoter (Bioneer 2016). The expression
system was controlled by T7 promoter, which could be in­
duced through inducing lactose analog compound, namely
isopropyl β­D­thiogalactoside (IPTG) (Rosano and Cecca­
relli 2014). pBT7­N­His­Fusion­NDV has a multi cloning
site (MCS) and stop codon (TGA) areas with nucleotide
sequences that can be digested by certain endonuclease
restriction enzymes. In this plasmid, there is a ribosome
binding site (RBS) that facilitates the translation process.
This vector plasmid also has pUC Ori which is an ini­
tial area for DNA replication. In addition, there is a β­
lactamase encoding gene which functions in the resistance
against ampicillin, which can be used in for selection of re­
combinant E. coli.
The expression of recombinant protein is a translation
process from gene into protein through the processes of
transcription and translation. Expression of protein could
be performed using a prokaryotic cell system with E. coli
or eukaryotic cells using yeast, filamentous fungi, and uni­
cellular algae. The selection of the host system depended
on the target protein which was going to be expressed. In
this research, the expression of recombinant NDV F pro­
tein was performed by using E. coli extract in a cell­free
protein expression system. This system was selected be­
cause a prokaryotic cell is one of the selected organisms to
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produce a recombinant protein (Wilson andWalker 2010).
In pBT7­N­His­Fusion­NDV expression plasmid, recom­
binant F protein is expressed as a fusion protein with 6x
his­tag (tag polyhistidine) at the N­terminus end. After
the purification process, the expressed recombinant F pro­
tein of NDV would be used as a candidate of recombinant
vaccine against ND based on Indonesian local isolate of
NDV strain. The existence of 6x his­tag in the recom­
binant F protein of NDV did not affect the structure and
function of the recombinant protein (Ramos et al. 2004).
Polyhistidine tag can function as the epitope for protein de­
tection in Western blot. Polyhistidine tag also functioned
for binding with Ni2+ in the protein purification process
(Sambrook and Green 2012). The benefit of using a poly­
histidine tag was the recombinant F protein could be pu­
rified in the denatured condition because the interaction
between histidine residue and Ni­NTA in the purification
column could be stable with the existence of strong pro­
tein denaturant as guanidine HCl and urea. The purified
recombinant protein can be renatured by slowly removing
the denaturant (Terpe 2003).
In order to obtain high gene expression, the expres­
sion can be performed on E. coli since it grows fast, the
enriched growth medium for E. coli is affordable, and the
process of DNA transformation on E. coli is fast and easy
(Qiagen 2001). E. coli BL21 (DE3) is a prokaryotic cell
used for gene expression regulated by T7 promoter. This
strain carries lysogen λDE3 containing lacI gene, RNA
polymerase T7 RNA controlled by lacUV5 promoter, and
a small part of lacZ gene (Wulanjati 2016). The expression
of the recombinant F protein of NDV could be influenced
by several factors, including vector plasmid, target protein,
and strain bacteria used in the protein expression. Vari­
ous internal factors of the plasmid which could influence
the expression are promoter, initiation region, terminator
region, enhancer, ribosome binding site, origin of replica­
tion, resistance marker against antibiotic, and the number
of plasmid copy. Meanwhile, other factors of target pro­
tein which could influence the expression are nucleotide
sequences, amino acid sequences, secondary structures of
the protein, and the suitable codon usage (Makrides 1996;
Rosano and Ceccarelli 2014). Besides, the productivity of
the recombinant protein expression could be enhanced by
optimization of external factors such as the temperature
of bacterial growth and the level of expression­inducing
compound (Chen et al. 2007; Volontè et al. 2008; Larentis
et al. 2011, 2014).
Expression of NDV F protein encoding gene have
been conducted by some researchers. For example, Chen
et al. (2001) conducted cloning and full­length expres­
sion of cDNA from NDV F gene isolate V4 (Queens­
land/66strain) on mammal’s cell in Chinese Hamster
Ovary (CHO­K1) and its mutant line cell Lec­ 3.2.8.1.
Park et al. (2014) developed a virus­like particles (VLP)
vaccine by expressing NDV F protein with Sf9 cell to
obtain recombinant protein of baculovirus (rBV). In this
work, we used local isolates of NDV from Kulon Progo,
Yogyakarta, Indonesia, whose pathotype characterization
has been identified by Haryanto et al. (2015). The re­
sult of this work showed that the recombinant F protein of
NDVwas successfully expressed by a cell­free protein ex­
pression system and visualized by using SDS­PAGE elec­
trophoresis with Coomassie Brilliant Blue staining and
Western blot as a specific protein with a molecular weight
of 25.6 kDa. This result was in line with the recombinant
protein study performed by other researchers, who have
successfully expressed the recombinant F protein of NDV
from E. coli clone of C­1a (Putri and Haryanto 2019).
The cell­free protein expression system is one of in
vitro protein expression methods to study biological reac­
tions in a cell using a living cell system that reduces com­
plex interactions on living cells, so the transcription, trans­
lation, and cell metabolism processes occur in an open en­
vironment. This system aims to understand, utilize, and
extend natural biological system capability without using
living cells (Hodgman and Jewett 2012). The expressed
recombinant F protein of NDV which had been purified,
had the potential as a candidate of recombinant F vaccine
for NDV based on the local isolate.
4. Conclusions
The fusion protein encoding gene of NDV subcloned into
the pBT7­N­His expression vector has been successfully
in vitro expressed by a cell­free protein expression system.
Visualization by using Coomassie Brilliant Blue staining
on SDS­PAGE gel and Western blot confirmed that the re­
combinant F protein of NDV expressed as a specific re­
combinant protein with a molecular weight of 25.6 kDa.
Acknowledgments
Wewould like to thank the head office of the Biochemistry
Department, Faculty of Veterinary Medicine, Universitas
GadjahMada (UGM), Yogyakarta, Indonesia and the head
office of Inter­University Center for Biotechnology UGM,
Yogyakarta, Indonesia for the opportunity and for allowing
us to use the laboratory facilities to finish this work.
Authors’ contributions
AH was responsible for the overall stage of research (re­
combinant plasmid preparation, laboratory works, draft­
ing, and completing the final manuscript). HW did sam­
ples preparation, performed the laboratory works, and an­
alyzed data. NW analyzed final data, drafted, and revised
the manuscript. All authors read and approved the final
version of the manuscript.
Competing interests
The authors declare no competing interest.
73
Haryanto et al. Indonesian Journal of Biotechnology 25(2), 2020, 69‐75
References
Alexander DJ. 2003. Newcastle Disease, Other Avian
Paramyxoviruses, and Pneumovirus Infections. In:
Y Salf, H Brnes, J Glisson, A Fadly, L Mc Douglad,
D Swayne, editors, Diseases of Poultry. Ames: Iowa
State Press, 11th edition. p. 63–100.
Alexander DJ, Aldous EW, Fuller CM. 2012. The long
view: a selective review of 40 years of Newcas­
tle disease research. Avian Pathol. 41(4):329–335.
doi:10.1080/03079457.2012.697991.
Arora P, Lakhchaura BD, Garg SK. 2010. Evaluation of
immunogenic potential of 75kDa and 56kDa proteins
of newcastle disease virus (NDV). Indian J Exp Biol
48(9):889–895.
Bioneer. 2016. Vector Information: pBT7­N­His.
Burgess RR. 2009. Chapter 17 Refolding Solubi­
lized Inclusion Body Proteins. In: RR Burgess,
MP Deutscher, editors, Methods in Enzymology:
Vol 463 Guide to Protein Purification, volume 463.
Academic Press Inc., 2nd edition. p. 259–282.
doi:10.1016/S0076­6879(09)63017­2.
Chang A, Dutch RE. 2012. Paramyxovirus fusion and en­
try: Multiple Paths to a common end. Viruses 4:613–
636. doi:10.3390/v4040613.
Chen L, Colman PM, Cosgrove LJ, Lawrence MC,
Lawrence LJ, Tulloch PA, Gorman JJ. 2001. Cloning,
expression, and crystallization of the fusion protein of
Newcastle disease virus. Virology 290(2):290–299.
doi:10.1006/viro.2001.1172.
Chen Y, Xing XH, Ye F, Kuang Y, Luo M. 2007.
Production of MBP­HepA fusion protein in re­
combinant Escherichia coli by optimization of cul­
ture medium. Biochem Eng J. 34(2):114–121.
doi:10.1016/j.bej.2006.11.020.
De Leeuw O, Peeters B. 1999. Complete nucleotide
sequence of Newcastle disease virus: Evidence for
the existence of a new genus within the subfam­
ily Paramyxovirinae. J Gen Virol. 80(1):131–136.
doi:10.1099/0022­1317­80­1­131.
De Mattos JC, Dantas FJ, Caldeira­De­Araújo A, Moraes
MO. 2004. Agarose gel electrophoresis sys­
tem in the classroom: Detection of DNA strand
breaks through the alteration of plasmid topol­
ogy. Biochem Mol Biol Educ. 32(4):254–257.
doi:10.1002/bmb.2004.494032040382.
Dharmayanti NI, Risza H, Dyah AH, Risa I. 2014. Phy­
logenetic analysis of genotype VII of new castle dis­
ease virus in Indonesia. African J Microbiol Res.
8(13):1368–1374. doi:10.5897/ajmr2014.6601.
Dortmans JC, Koch G, Rottier PJ, Peeters BP. 2011. Vir­
ulence of newcastle disease virus: What is known so
far? Vet Res. 42(1). doi:10.1186/1297­9716­42­122.
Ganar K, Das M, Sinha S, Kumar S. 2014. New­
castle disease virus: Current status and
our understanding. Virus Res. 184:71–81.
doi:10.1016/j.virusres.2014.02.016.
Grand LRL, White M, Siegel EB, Barnard RT. 2012.
Recombinant Vaccines: Development, Production,
and Application. In: O Kayser, H Warzecha, edi­
tors, Pharmaceutical Biotechnology: Drug Discovery
and Clinical Applications, chapter 17. Hoboken (NJ):
John Wiley & Sons, Ltd}„ 2nd edition. p. 423—­449.
doi:10.1002/9783527632909.ch17.
Haryanto A, Ermawati R, Wati V, Irianingsih SH, Wi­
jayanti N. 2016. Analysis of viral protein­2 encoding
gene of avian encephalomyelitis virus from field spec­
imens in Central Java region, Indonesia. Vet World.
9(1):25–31. doi:10.14202/vetworld.2016.25­31.
Haryanto A, Purwaningrum M, Verawati S, Irian­
ingsih SH, Wijayanti N. 2015. Pathotyping
of Local Isolates Newcastle Disease Virus from
Field Specimens by RT­PCR and Restriction En­
donuclease Analysis. Procedia Chem. 14:85–90.
doi:10.1016/j.proche.2015.03.013.
Hodgman CE, Jewett MC. 2012. Cell­free synthetic
biology: Thinking outside the cell. Metab Eng.
14(3):261–269. doi:10.1016/j.ymben.2011.09.002.
Jeon WJ, Lee EK, Lee YJ, Jeong OM, Kim YJ, Kwon JH,
Choi KS. 2008. Protective efficacy of commercial in­
activated Newcastle disease virus vaccines in chick­
ens against a recent Korean epizootic strain. J Vet Sci.
9(3):295–300. doi:10.4142/jvs.2008.9.3.295.
Kim SH, Wanasen N, Paldurai A, Xiao S, Collins PL,
Samal SK. 2013. Newcastle Disease Virus Fusion
Protein Is the Major Contributor to Protective Immu­
nity of Genotype­Matched Vaccine. PLoS ONE 8(8).
doi:10.1371/journal.pone.0074022.
King AM, Adams MJ, Carstens EB, Lefkowitz EJ. 2012.
Virus Taxonomy: Classification and Nomenclature of
Viruses. Elsevier. doi:10.1016/B978­0­12­384684­
6.00057­4.
Lamb R, Parks G. 2007. Fields’ Virology, Volume 1.
In: BN Fields, DM Knipe, PM Howley, editors,
Paramyxoviridae: the viruses and their replication.
Philadelphia: Lippincott, Williams and Wilkins, 5th
edition. p. 1449–1496.
Larentis AL,Nicolau JFMQ, EstevesGDS,Vareschini DT,
De Almeida FVR, Dos Reis MG, Galler R, Medeiros
MA. 2014. Evaluation of pre­induction temperature,
cell growth at induction and IPTG concentration on
the expression of a leptospiral protein in E. coli using
shaking flasks and microbioreactor. BMC Res Notes.
7(1). doi:10.1186/1756­0500­7­671.
Larentis AL, Sampaio HDCC, Martins OB, Rodrigues
MI, Alves TLM. 2011. Influence of induction con­
ditions on the expression of carbazole dioxygenase
components (CarAa, CarAc, and CarAd) from Pseu­
domonas stutzeri in recombinant Escherichia coli us­
ing experimental design. J Ind Microbiol Biotechnol.
38(8):1045–1054. doi:10.1007/s10295­010­0879­2.
Makrides SC. 1996. Strategies for achieving high­level
expression of genes in Escherichia coli. Microbiol
Rev. 60(3):512–538. doi:10.1128/mmbr.60.3.512­
538.1996.
Middelberg AP. 2002. Preparative protein re­
74
Haryanto et al. Indonesian Journal of Biotechnology 25(2), 2020, 69‐75
folding. Trends Biotechnol. 20(10):437–443.
doi:10.1016/S0167­7799(02)02047­4.
Miller PJ, King DJ, Afonso CL, Suarez DL. 2007.
Antigenic differences among Newcastle disease
virus strains of different genotypes used in vac­
cine formulation affect viral shedding after a
virulent challenge. Vaccine 25(41):7238–7246.
doi:10.1016/j.vaccine.2007.07.017.
Morrison TG. 2003. Structure and function of a paramyx­
ovirus fusion protein. Biochim Biophys Acta,
Biomembr. 1614(1):73–84. doi:10.1016/S0005­
2736(03)00164­0.
Nascimento IP, Leite LC. 2012. Recombinant vac­
cines and the development of new vaccine strate­
gies. Brazilian J Med Biol Res. 45(12):1102–1111.
doi:10.1590/S0100­879X2012007500142.
Njoto EN, Scotch M, Bui CM, Adam DC, Chughtai AA,
MacIntyre CR. 2018. Phylogeography of H5N1 avian
influenza virus in Indonesia. Transboundary Emerg­
ing Dis. 65(5):1339–1347. doi:10.1111/tbed.12883.
[OIE] Office International of Epizootics. 2012. Newcastle
disease infection with newcastle disease virus.
[OIE] Office Internationalof Epizootics. 2015. Old classi­




Parede LH, Sapats S, Gould G, Rudd M, Lowther S,
Ignjatovic J. 2003. Characterization of infectious
bursal disease virus isolates from Indonesia indi­
cates the existence of very virulent strains with
unique genetic changes. Avian Pathol. 32(5):511–
518. doi:10.1080/0307945031000154116.
Park JK, Lee DH, Yuk SS, Tseren­Ochir EO, Kwon JH,
Noh JY, Kim BY, Choi SW, Kang SM, Lee JB, et al.
2014. Virus­like particle vaccine confers protection
against a lethal newcastle disease virus challenge in
chickens and allows a strategy of differentiating in­
fected from vaccinated animals. Clin Vaccine Im­
munol. 21(3):360–365. doi:10.1128/CVI.00636­13.
Putri CN, Haryanto A. 2019. Fusion recombinant pro­
tein expression of newcastle disease virus from Es­
cherichia coli­Cloned C1a using accurapidTMprotein
expression kit. IOP Conference Series: Earth and
Environmental Science 355(1). doi:10.1088/1755­
1315/355/1/012026.
Qiagen. 2001. The QIA expressionist: a handbook
for high­level expression and purification of 6xHis­
tagged protein.
Ramos CR, Abreu PA, Nascimento AL, Ho PL. 2004. A
high­copy T7 Escherichia coli expression vector for
the production of recombinant proteins with a mini­
mal N­terminal his­tagged fusion peptide. Brazillian J
Med Biol Res. 37(8):1103–1109. doi:10.1590/S0100­
879X2004000800001.
Rosano GL, Ceccarelli EA. 2014. Recombinant pro­
tein expression in Escherichia coli: Advances and
challenges. Frontiers in Microbiology 5(APR).
doi:10.3389/fmicb.2014.00172.
Sambrook J, Green M. 2012. Molecular Cloning: A Lab­
oratory Manual. New York: Cold Spring Harbor Lab­
oratory Press, 4th edition.
Terpe K. 2003. Overview of tag protein fusions: From
molecular and biochemical fundamentals to commer­
cial systems. Appl Microbiol Biotechnol. 60(5):523–
533. doi:10.1007/s00253­002­1158­6.
Volontè F, Marinelli F, Gastaldo L, Sacchi S, Pilone
MS, Pollegioni L, Molla G. 2008. Optimization
of glutaryl­7­aminocephalosporanic acid acylase ex­
pression in E. coli. Protein Expression Purif.
61(2):131–137. doi:10.1016/j.pep.2008.05.010.
Wilson K, Walker J. 2010. Principles and Techniques
of Biochemistry and Molecular Biology. Cam­
bridge: Cambrige University Press, 7th edition.
doi:10.1017/cbo9780511841477.
Wulanjati M. 2016. Ekspresi protein rekombinan Fu­
sion (F) virus Newcastle disease isolat lokal pada
Escherichia coli BL21 (DE3) [Expression of re­
combinant Fusion (F) protein of Newcastle Disease
Virus from local isolates on Escherichia coli BL­21
(DE.3)]. Master thesis, Universitas Gadjah Mada.
Wulanjati MP, Wijayanti N, Haryanto A. 2018. Phylo­
genetic analysis of Newcastle disease virus from In­
donesian isolates based on DNA­sequence of fusion
protein­encoding gene. Biotechnology 17(2):69–74.
doi:10.3923/biotech.2018.69.74.
Xiao S, Paldurai A, Nayak B, Samuel A, Bharoto
EE, Prajitno TY, Collins PL, Samal SK. 2012.
Complete Genome Sequences of Newcastle Dis­
ease Virus Strains Circulating in Chicken Popula­
tions of Indonesia. J Virol. 86(10):5969–5970.
doi:10.1128/jvi.00546­12.
Yang Z, Zhang L, Zhang Y, Zhang T, Feng Y, Lu
X, Lan W, Wang J, Wu H, Cao C, Wang X.
2011. Highly efficient production of soluble pro­
teins from insoluble inclusion bodies by a Two­Step­
Denaturing and refolding method. PLoS ONE 6(7).
doi:10.1371/journal.pone.0022981.
75
